Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $51 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on PTC Therapeutics (NASDAQ:PTCT) and maintained a price target of $51.
December 18, 2023 | 2:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst reaffirms Overweight rating on PTC Therapeutics with a steady price target of $51, indicating a positive outlook on the stock.
The reiteration of an Overweight rating by a reputable analyst such as Kristen Kluska from Cantor Fitzgerald, along with the maintenance of a $51 price target, suggests a strong vote of confidence in PTC Therapeutics. This endorsement is likely to be viewed positively by investors and could lead to a short-term increase in the stock price, assuming market conditions do not change significantly.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100